AwardedSWEGoodsFramework agreementSEK 99,000,000
Läkemedel 2026 del 2
- Published
- Published 31 March 2026
- Deadline
- Closed 4 May 2026
Overview
Region Skåne has awarded a pharmaceutical supply contract for three active substances—sugammadex, ustekinumab, and kapsaicin—to be supplied successively to the region and contracted private healthcare providers. The contract, valued at approximately 99 million SEK, was awarded on 3 June 2026 to nine suppliers: Biocon Biologics Ireland Limited, Celltrion Sweden AB, Fresenius Kabi AB, Grunenthal Sweden AB, STADA Nordic ApS, Sandoz A/S, Viatris AB, Zentiva Denmark ApS, and Øresund Pharma ApS.
Key details
- Country
- SWE
- Status
- Awarded
- Category
- Goods
- Estimated value
- SEK 99,000,000
- Procedure
- Open
- Contract type
- Framework agreement
- SME suitable
- Yes
- Published
- 31 March 2026
- Deadline
- Closed
Medical equipments, pharmaceuticals and personal care productsPharmaceutical products
Award outcome
- Award date
- 3 June 2026
- Contract period
- 1 September 2026 → 31 August 2028
- Biocon Biologics Ireland Limited
- Celltrion Sweden AB
- Fresenius Kabi AB
- Grunenthal Sweden AB
- STADA Nordic ApS
- Sandoz A/S
- Viatris AB
- Zentiva Denmark ApS
- Øresund Pharma ApS
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
8 July 2026
Contract Notice
31 March 2026
Contracting authority
Region Skåne, Koncernstab inköp och ekonomistyrning
Procuring entityKRISTIANSTAD, SWE
002: 2321000255
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.